Gregory A. Ciongoli was appointed Director of Gossamer Bio, Inc., effective September 16, 2026. As of November 7, 2026, Gossamer Bio, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 16, 2026, naming 2 appointments (Form 8-K, September 16, 2026).
Gossamer Bio, Inc. named a new Director on Sep 16. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Gossamer Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Gossamer Bio, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-16. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Gossamer Bio, Inc. files it.
Also on the record for Gossamer Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 10.9% of the class | 5%+ stakes | Source |
| November 6, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 6.98% of the class | 5%+ stakes | Source |
| October 29, 2026 | Stake report, Schedule 13D/A, by D. E. Shaw & Co., L.P. | 4.2% of the class | 5%+ stakes | Source |
| October 8, 2026 | Stake report, Schedule 13D/A, by D. E. Shaw & Co., L.P. | 6% of the class | 5%+ stakes | Source |
| September 28, 2026 | Stake report, Schedule 13D/A, by D. E. Shaw & Co., L.P. | 5.1% of the class | 5%+ stakes | Source |
| September 4, 2026 | Form D, private offering | $25M sold | Form D page | Source |
| August 24, 2026 | Stake report, Schedule 13D/A, by D. E. Shaw & Co., L.P. | 6% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by Opaleye Management Inc. | 5.1% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1% of the class | 5%+ stakes | Source |
| July 24, 2026 | Stake report, Schedule 13D/A, by D. E. Shaw & Co., L.P. | 7.1% of the class | 5%+ stakes | Source |
| July 1, 2026 | Stake report, Schedule 13D/A, by D. E. Shaw & Co., L.P. | 8.3% of the class | 5%+ stakes | Source |
| June 19, 2026 | Court case: Sparks v. Gossamer Bio, Inc., District Court, S.D. California | — | Court records | Source |
Selling to them or working with them? See who runs Gossamer Bio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Gossamer Bio, Inc. and the records around it.
Gossamer Bio, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Company profile and every filing Sep 2026
- Form D filing Sep 2026
- Who owns it
Companies that share a holder
- Growth Equity Opportunities 18 VGE, LLC also filed stake reports on 2 other companies: Celcuity Inc. (Mar 2026), X4 Pharmaceuticals, Inc. (Oct 2025)
- Context Capital Management, LLC also filed stake reports on 8 other companies: BOA Acquisition Corp. II (Aug 2026), Cartesian Growth Corp II (Aug 2026), Plum Acquisition Corp, IV (Jul 2026)
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026)
Watch Gossamer Bio, Inc.
Get an email when Gossamer Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Gossamer Bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Gossamer Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Gossamer Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 27 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-16 | In | Director | 2026-09-16 | 8-K, 2026-09-16 | |
| 2026-09-16 | In | 8-K, 2026-09-16 |
Who leads Gossamer Bio, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Gregory A. Ciongoli, appointed, effective 2026-09-16 (filed 2026-09-16).
New leaders reset buying decisions — get the Full Report on Gossamer Bio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Gossamer Bio, Inc. (free up to 3)
Find people with the same kind of experience as the Director at Gossamer Bio, Inc., with the record behind each one.
Find candidates like Director at Gossamer Bio, Inc.Every change, in the filing's words
Appointed: Gregory A. Ciongoli, Director, effective 2026-09-16
On September 16, 2026, upon the recommendation of the Nominating and Corporate Governance Committee, pursuant to the amended and restated bylaws of Gossamer Bio, Inc. (the "Company"), the Board of Directors (the "Board") of the Company appointed Gregory A. Ciongoli to serve as a Class III director, effective September 16, 2026, with an initial term expiring at the Company's 2027 annual meeting of stockholders.
Appointed: Gregory A. Ciongoli
The Board also appointed Mr. Ciongoli as a member of the Audit Committee.
- Mr. Ciongoli, age 51, has served as the Founder and Managing Partner of Adiumentum Capital Management, a Boston-based investment firm, since April 2024.
- Prior to Adiumentum, he was a Partner at the Baupost Group from 2007 to 2024, where he worked on a broad range of public and private equity investments.
- Mr. Ciongoli has served on the boards of directors of REGENXBIO Inc. since August 2026, Zymeworks, Inc. since August 2025 and Atara Biotherapeutics, Inc. since September 2024, having served as chair of the Board of Atara since September 2025.
- Mr. Ciongoli is also actively involved in a number of local not-for-profit organizations.
- Mr. Ciongoli graduated from Princeton University with an A.B. and received his M.B.A. from Harvard Business School.
- Pursuant to the Company's non-employee director compensation program, Mr. Ciongoli (i) will receive an annual cash retainer of $40,000 for service on the Board and (ii) an annual cash retainer of $7,500 for service on the Audit Committee.
- In addition, Mr. Ciongoli will be entitled to equity compensation specified in the Company's non-employee director compensation program, although the Board determined that a standard initial award to Mr. Ciongoli will be made at a future date, and in a future amount, to be determined by the Board.
Gossamer Bio, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Gossamer Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.